Glimepiride Tablet Formulation and Evaluation Using Solid Dispersion for Enhanced Bioavailability

The current study focuses on the formulation and evaluation of Glimepiride 4 mg tablets with the goal of increasing bioavailability and thereby improving therapeutic efficacy in the treatment of type 2 diabetes. Glimepiride, a second-generation sulfonylurea, has low water solubility, resulting in inconsistent and often insufficient oral bioavailability. To address this issue, formulation strategies were used, such as PEG 6000, β-cyclodextrin, superdisintegrants, and solid dispersion techniques. The tablets were compressed directly and assessed for pre- and post-compression parameters such as flow properties, hardness, friability, weight variation, disintegration time, drug content uniformity, and in vitro drug release. When compared to normal tablets, optimized formulations revealed much faster dissolving The in vitro drug release profile revealed a prolonged and enhanced release of Glimepiride, indicating greater solubility and potential for increased bioavailability. Stability investigations conducted in accordance with ICH criteria demonstrated the physical and chemical stability of the improved formulation. The findings indicate that the new Glimepiride 4 mg tablets provide a promising strategy to improving bioavailability and therapeutic effectiveness, potentially allowing for more consistent glycemic control in diabetic patients. Additional in vivo investigations are needed to establish the improved pharmacokinetic profile